Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35031 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Barbara Melosky und 9 weiteren Autor:innen. Beteiligte Einrichtung: BCCA Vancouver Centre, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Canada, AstraZeneca Canada, Merck Canada.
Abstract (Originalsprache)
Cure of cancer is a sensitive and multidimensional concept that is challenging to define, difficult to assert at the individual patient level, and often surrounded by controversy. The notion of cure in non‐small cell lung cancer (NSCLC) has changed and continues to evolve with improvements in diagnosis and treatment. Targeted and immune therapies have recently entered the treatment landscape of stage I–III NSCLC. While some initial pivotal trials of such agents failed to improve survival, recently approved epidermal growth factor receptor (EGFR) inhibitors (in EGFR‐mutated NSCLC) and immune checkpoint inhibitors have shown delays in disease recurrence or progression and unprecedented survival gains compared to previous standards of care. Additional data is now emerging supporting the benefit of treatment strategies based on alternation‐matched targeting (anaplastic lymphoma kinase [ALK] inhibition in ALK‐altered disease) and immune checkpoint inhibition in stage I–III NSCLC. Similar to previous developments in the treatment of early and locally advanced NSCLC, it is expected that statistically significant and clinically meaningful trial‐level benefits will translate into real‐world benefits, including improvements in cure measures. Parallel advances in molecular testing (e.g., circulating tumor DNA analyses) are also allowing for a deeper and more comprehensive characterization of disease status and treatment response. Given the impact that curative‐intent treatments have on survival, it is critical that various stakeholders, including clinicians and patients, are aware of new opportunities to pursue cure in stage I–III NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BCCA Vancouver Centre, University of British Columbia, Vancouver, British Columbia, Canada.
- London Regional Cancer Centre, University of Western Ontario, London, Ontario, Canada.
- Vancouver Coastal Health Research Institute, University of British Colombia, Vancouver, British Columbia, Canada.
- Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada.
- Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
- William Osler Health System, University of Toronto, Brampton, Ontario, Canada.
ORCID-Profile: Barbara Melosky
Förderung
- Roche Canada
- AstraZeneca Canada
- Merck Canada
Zitieren
APA
Melosky, B., Vincent, M. D., McGuire, A. L., Brade, A. M., Chu, Q., Cheema, P., Martins, I., Spicer, J. D., Snow, S., & Juergens, R. A. (2024). Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.35031
Vancouver
Melosky B, Vincent MD, McGuire AL, Brade AM, Chu Q, Cheema P, et al. Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer. International Journal of Cancer. 2024. doi:10.1002/ijc.35031
BibTeX
@article{Melosky2024,
author = {Melosky, Barbara and Vincent, Mark D and McGuire, Anna L and Brade, Anthony M and Chu, Quincy and Cheema, Parneet and Martins, Ilidio and Spicer, Jonathan D and Snow, Stephanie and Juergens, Rosalyn A},
title = {Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35031}
}
EUVIMED